Medications for Alcohol Use Disorder

Alcohol use disorder (AUD) is a chronic, relapsing health condition characterized by impaired control over alcohol use and continued consumption despite harm. Pharmacological treatment is generally used alongside psychosocial care, withdrawal management, and recovery support. Evidence-based options include naltrexone, acamprosate, and disulfiram in appropriate patients, while treatment selection depends on clinical history, treatment goals, comorbidities, liver and kidney function, concurrent medicines, pregnancy considerations, and access to follow-up care. The central implementation challenge is translating proven efficacy into routine, sustained treatment for people who remain underdiagnosed or undertreated.

The treatment landscape is moving away from viewing AUD care as a short detoxification episode and toward longitudinal management that combines screening, withdrawal safety assessment, medication, counseling, and relapse-prevention support. Shared decision-making is increasingly important because medicines differ in mechanism, dosing schedule, contraindications, and suitability for abstinence or reduced drinking goals. Primary care, emergency services, addiction specialty care, mental-health services, and community programs are being encouraged to coordinate care, while telehealth and digital follow-up can help extend access when clinical governance, privacy, and escalation pathways are defined.

Artificial intelligence may support AUD care by identifying risk patterns in clinical records, prioritizing screening, assisting documentation, tailoring reminders, and detecting signals associated with missed follow-up or recurrence of heavy drinking. These applications should augment rather than replace clinician judgment. Reliable deployment requires representative training data, transparent validation, protection against bias, secure handling of sensitive behavioral-health information, and clear human review for diagnosis, medication selection, withdrawal risk, and urgent safety concerns. AI-generated recommendations should be tied to established clinical guidelines and monitored for unintended effects, including stigmatizing labels or inappropriate treatment escalation.

North America has established evidence-based pharmacotherapy and specialist infrastructure, but treatment gaps, affordability, fragmented services, and uneven primary-care adoption remain important barriers. Europe benefits from mature public-health and addiction-care systems, although national guidance, reimbursement, and service pathways vary. Asia-Pacific combines rapidly expanding health capacity with substantial differences in screening, stigma, rural access, and regulatory availability. Latin America faces uneven specialist coverage and financing, increasing the importance of primary-care integration and community-based support. In the Middle East, cultural considerations, confidentiality, and limited specialized services can shape help-seeking and delivery. Africa requires approaches suited to constrained workforces, medicine availability challenges, comorbidity, and geographically dispersed populations.

ASEAN countries face wide variation in health-system capacity, regulatory practice, and specialist availability, making adaptable screening and referral models valuable. BRICS members span different burdens, treatment infrastructures, and financing arrangements; cooperation on training, essential medicines, and implementation evidence could support more consistent care. The European Union can benefit from cross-border learning while retaining country-specific clinical and reimbursement decisions. G7 systems generally possess stronger research and clinical capacity, but still need to close diagnosis and retention gaps. GCC countries can emphasize confidential, culturally responsive services and workforce development. NATO members may benefit from coordinated approaches to alcohol-related health risks among military personnel and veterans, while preserving national clinical governance.

Australia combines established addiction services with opportunities to expand routine primary-care treatment and rural access. Brazil and Mexico must address uneven specialist coverage, affordability, and integration across public and private care. Canada and the United States have broad clinical evidence and multiple treatment settings, but stigma, insurance or provincial variation, and fragmented follow-up affect reach. China and India require scalable screening, culturally appropriate engagement, and stronger linkage between general medical and specialty services. Japan and South Korea face the need to improve early identification and continuity while accounting for social stigma and workplace impacts. France, Germany, Italy, Spain, and the United Kingdom have developed health and addiction systems, yet national differences in reimbursement, prescribing pathways, and service capacity remain material. Russia requires attention to continuity, comorbid conditions, and evidence-aligned care access within its health-system context.

Industry leaders should embed validated AUD screening and medication pathways in primary care, emergency departments, mental-health services, and other high-contact settings. They should support clinician training on diagnosis, withdrawal risk, contraindications, shared decision-making, and follow-up; strengthen referral links with psychosocial and recovery services; and design adherence support around patient preferences rather than one-size-fits-all assumptions. Access strategies should address rural and underserved communities through telehealth, mobile services, and community partnerships where appropriate. Organizations should track initiation, retention, safety monitoring, patient-reported outcomes, and equity across demographic groups. Any digital or AI-enabled tool should undergo clinical validation, privacy review, bias testing, and continuous post-deployment monitoring.

This executive summary is based on established clinical knowledge concerning AUD pharmacotherapy, treatment delivery, and health-system implementation. The synthesis considers recognized treatment principles, including medication use alongside psychosocial care, patient selection, safety monitoring, access barriers, and continuity of care. Regional, group, and country observations are framed as qualitative system-level insights rather than quantitative comparisons. No market estimates, forecasts, market shares, or company-specific claims are presented. Interpretation should be supplemented with current national guidelines, regulatory information, local epidemiology, reimbursement rules, and service-capacity assessments before operational decisions are made.

Medications for AUD are most effective as part of coordinated, person-centered care that addresses withdrawal safety, long-term treatment, mental and physical comorbidity, and recovery goals. The main opportunity is not simply the existence of effective medicines, but their consistent delivery to people who need them, with appropriate follow-up and reduced stigma. Leaders should prioritize integrated pathways, workforce capability, equitable access, responsible digital innovation, and measurement of patient-centered outcomes. Regional and national adaptation will be essential because regulatory systems, cultures, resources, and care models differ substantially across the covered geographies.